Revvity raises guidance, buys metabolic cell model maker
Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.